在临床开发中选NLRP3候选药物:从现有和新兴技术中吸取教训
Isak W Tengesdal1, Migachelle Banks1, Charles A Dinarello1
1Department of Medicine, University of Colorado Denver, Aurora, CO, United States.
Frontiers in immunology
|August 27, 2024
概括
针对NLRP3激活,这是炎症的关键媒介,为各种疾病提供了一个有前途的治疗策略. 针对NLRP3的小分子显示出转化潜力,目前正在努力开发有效的选技术.
科学领域:
- 免疫学和分子生物学
- 药物发现和开发 药物发现和开发
背景情况:
- 介素-1β (IL-1β) 是炎症性疾病中的关键细胞因子,现有的生物药物显示出可变的安全性.
- 在IL-1β上游的NLRP3炎症酶激活与神经退行性疾病,心脏代谢综合征和癌症有关.
- 临床前研究表明,NLRP3.3的遗传和药理抑制是有效的.
研究的目的:
- 审查针对具有转化潜力的NLRP3的小,口服活性分子的特性.
- 讨论目前用于选NLRP3向分子的技术.
主要方法:
- 对NLRP3抑制剂的临床前和临床研究的文献综述.
- 对NLRP3调制器的选技术的分析.
主要成果:
- 一些针对NLRP3的小分子正在临床开发中.
- 存在各种选平台,每个都有不同的优势和局限性.
结论:
- 准NLRP3代表了炎症状况的重要治疗途径.
- 开发有效的查方法对于推进NLRP3向疗法至关重要.
相关概念视频
Drug Discovery: Overview
10.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.4K
Preclinical Development: Overview
4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K


